Showing results (1451-1460 of 1,508) with videos related to

Sort By:
Pageof 151
Journal of Sleep Research|July 9, 2025
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled TrialAnastasia Suraev, Iain S McGregor, Danielle McCartney, et al.
Vaccine|December 20, 2023
Vaccine value profile for Neisseria gonorrhoeaeYiming Lyu, Annabelle Choong, Eric P F Chow, et al.
Journal of Neuroinflammation|December 21, 2018
Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PETJennifer M Coughlin, Ting Yang, Alison W Rebman, et al.
The Lancet. Infectious Diseases|July 25, 2021
The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigationBart J Currie, Mark Mayo, Linda M Ward, et al.
Journal of the American Heart Association|December 5, 2019
Geographic Analysis of Mobile Stroke Unit Treatment in a Dense Urban Area: The New York City METRONOME RegistryBenjamin R Kummer, Mackenzie P Lerario, Madeleine D Hunter, et al.
Bioorganic & Medicinal Chemistry|December 20, 2011
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitorsJackie D Kendall, Patrick D O'Connor, Andrew J Marshall, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2025
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodyKarthik Ramasamy, Ravi Vij, David Kuter, et al.
Journal of the American Veterinary Medical Association|January 3, 2024
Animal drug shortages limit veterinary therapeutic options and introduce artifacts in antimicrobial sales reporting, Rebecca C Robbins, Randall S Singer, et al.
Cell|September 20, 2024
Microbial colonization programs are structured by breastfeeding and guide healthy respiratory developmentLiat Shenhav, Kelsey Fehr, Myrtha E Reyna, et al.
The Journal of Infection|November 16, 2024
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years oldC McLeod, M Dymock, K L Flanagan, et al.
Pageof 151